Morbois-Trabut L, Chabrolle C, Garrigue M A, Lasfargues G, Lecomte P
Unité d'Endocrinologie, Diabétologie, Maladies Métaboliques, CHRU Bretonneau, Tours, France.
Diabetes Metab. 2006 Jun;32(3):270-5. doi: 10.1016/s1262-3636(07)70279-3.
Apo E polymorphism has been shown to affect lipid profiles in non-diabetic and diabetic populations. We evaluated the relationship between Apo E phenotype and fasting lipid plasma levels in type 2 diabetes patients.
Two hundred and ten French type 2 diabetic patients (115 men and 95 women) without any lipid lowering drugs were studied. Fasting lipids were measured by usual methods and Apo E genotype was established for each patient: PCR was followed by digestion of the amplification product with restriction enzymes and separation of the fragments by polyacrylamide gel.
Genotypes epsilon3/epsilon3, epsilon2/epsilon3 and epsilon3/epsilon4, epsilon2/epsilon2 and epsilon2/epsilon4 were found in 68.1%, 14.8%, 15.7%, 1.0% and 0.5%, respectively. No patient had the epsilon4/epsilon4 genotype. Lipid plasma levels were compared between E3 group (epsilon3/epsilon3) as a reference and E2 (epsilon2/epsilon2 or epsilon2/epsilon3) or E4 (epsilon3/epsilon4 or epsilon2/epsilon4). Total cholesterol, LDL cholesterol and Apo B levels were lower in the E2 group. Total cholesterol, LDL cholesterol and Apo B levels were higher in the E4 group. HDL cholesterol levels were increased in the E4 group, as only previously observed in Japanese populations.
These results agree with those already reported in diabetic patients of several western European countries. E4 allele carriers have a greater cardio-vascular risk and this could be partially explained by the metabolic variation in lipid metabolism induced by E4 with higher LDL cholesterol and Apo B levels. These results observed in French diabetic subjects without any lipid-lowering drugs may be used as a reference for other studies performed in France.
载脂蛋白E（Apo E）多态性已被证明会影响非糖尿病和糖尿病患者的血脂谱。我们评估了2型糖尿病患者Apo E表型与空腹血脂水平之间的关系。
对210名未服用任何降脂药物的法国2型糖尿病患者（115名男性和95名女性）进行了研究。采用常规方法测量空腹血脂，并为每位患者确定Apo E基因型：先进行聚合酶链反应（PCR），然后用限制性内切酶消化扩增产物，并通过聚丙烯酰胺凝胶分离片段。
分别发现ε3/ε3、ε2/ε3和ε3/ε4、ε2/ε2和ε2/ε4基因型的患者比例为68.1%、14.8%、15.7%、1.0%和0.5%。没有患者具有ε4/ε4基因型。以E3组（ε3/ε3）为参照，比较E2组（ε2/ε2或ε2/ε3）或E4组（ε3/ε4或ε2/ε4）的血脂水平。E2组的总胆固醇、低密度脂蛋白胆固醇和载脂蛋白B水平较低。E4组的总胆固醇、低密度脂蛋白胆固醇和载脂蛋白B水平较高。E4组的高密度脂蛋白胆固醇水平升高，这与之前在日本人群中观察到的情况一致。
这些结果与几个西欧国家糖尿病患者的报道一致。E4等位基因携带者具有更高的心血管风险，这可能部分归因于E4诱导的脂质代谢变化，导致低密度脂蛋白胆固醇和载脂蛋白B水平升高。在未服用任何降脂药物的法国糖尿病患者中观察到的这些结果，可作为法国其他研究的参考。
